Table 2 Cost effectiveness analysis
From: OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis
Strategy | Cost (US$) | Diff ($) | QUALYs | Diff (QALYs) | NMB($) |
|---|---|---|---|---|---|
OM-85 BV | 843 | 0.91 | 4119 | ||
PLACEBO | 1167 | 594 | 0.89 | 0.01 | 3724 |
From: OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis
Strategy | Cost (US$) | Diff ($) | QUALYs | Diff (QALYs) | NMB($) |
|---|---|---|---|---|---|
OM-85 BV | 843 | 0.91 | 4119 | ||
PLACEBO | 1167 | 594 | 0.89 | 0.01 | 3724 |